Hearing Loss clinical trials at UCLA
2 in progress, 1 open to eligible people
DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
open to eligible people ages up to 17 years
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: - Learn about the safety of DB-OTO - Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) - Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Los Angeles, California and other locations
Cochlear Implant With Dexamethasone Eluting Electrode Array
Sorry, in progress, not accepting new patients
An evaluation of Cochlear's cochlear implant electrode array which passively elutes dexamethasone for a defined period of time to help reduce inflammatory responses.
Los Angeles, California and other locations
Our lead scientists for Hearing Loss research studies include Akira Ishiyama.
Last updated: